BRANFORD, Conn.--(BUSINESS WIRE)--Neurogen Corporation (Nasdaq: NRGN), a drug discovery and development company, announced today that it has filed a $100 million universal shelf registration statement on Form S-3 with the Securities and Exchange Commission (SEC), which will permit it, from time to time, to offer and sell debt securities, shares of its common stock or preferred stock, or warrants to purchase its debt securities, common stock, or preferred stock (collectively the “Securities”).
